Strategy & Operations Leader: Lead delivery of business critical Oncology R&D (ORD) Chief Operating Officer (COO) programs and BAU business planning activities; provide strategic input for initiatives across COO functions.Global Head of PMO: Lead global team across US, UK, Spain and Canada of 40 FTEs and various contractors to drive non-drug transformational, strategic priorities through 4 key pillars:1. Program and project management2. Change management3. Process and productivity management4. Business insights and data-driven decision-makingSite Leadership Team Sponsor: Also, sponsor key strategic and employee engagement initiatives as Oncology R&D representative on Gaithersburg (Maryland) Site Leadership Team, overseeing 5000+ local employees; in 2023, led strategic efforts related to long-term site (office and lab) vision and master planning

• Lead critical cross-functional, transformational (non-drug) programs across global Oncology R&D with focus on driving increased efficiency and effectiveness through the Chief Operating Officer Program Management Office. Drive cost savings, increases in productivity and overall program optimization for key global initiatives, including drug development patient identification / selection and Research to Commercial data sciences / infrastructure builds. Support various other global enterprise level (cross R&D and Commercial) strategic projects• Sponsor key initiatives as Oncology R&D representative on Gaithersburg (Maryland) Site Leadership Team, overseeing 5000+ local employees; drive strategic efforts related to long-term site vision and planning

• Led operational efficiency and effectiveness initiatives with demonstrated positive impact on Onc R&D organization - for example: developing our global long-term R&D office and lab site footprint strategy (through understanding headcount demand and site capacity), optimizing our hybrid F2F/virtual approach to Tier 1 Oncology congresses to maximize benefit for all, facilitating development of our holistic, global R&D Learning & Development strategy and leading the delivery of our first-ever Oncology Leadership Summit (OLS) event bringing together 500 Oncology leaders from across R&D, Commercial and Medical Affairs for a 3-day virtual workshop • Led Oncology R&D global business planning and operations network of 10+ functional areas, with focus on delivering key business process activities, connecting to key enabling functions (e.g., HR, Finance, Communications, etc) and enhancing operational excellence• Supported management of Onc R&D COO Non-Drug Project (NDP) portfolio; developed initial framework for COO PMO model and structure to further refine• Sponsored key initiatives as Oncology R&D representative on Gaithersburg (Maryland) Site Leadership Team, overseeing 5000+ local employees• Coached and mentored cross-functional Project Managers; people line manager of 4 Project Managers in 2020-2021 with strong focus on people development and growth opportunities

• Directly supported EVP ORD (Dr. Jose Baselga) as his Chief of Staff• Delivered key strategic initiatives and efficiency NDP projects, ensuring collaboration across Oncology R&D functional teams from preclinical to phase 3 studies (Clinical, Translational, Discovery, Biometrics, Regulatory, Strategy, BD, Digital, CMO, Global markets and teams, etc)• Drove critical business and operational activities in close partnership with enabling functions (Finance, HR, Comms, Legal, Project/Portfolio Mgmt and others) and other enterprise business areas (Biopharm R&D, OBU, BBU, Operations, etc)• Managed team of 8 operational leaders and project managers to deliver 30+ operational / non-drug project initiatives, activities, events and projects• Received strong Pulse survey scores that represent our operational management team is a great place to work (85% agree) and leadership communications is robust and transparent (90% agree)• Managed 20-person ORD cross-functional senior leadership team (including driving agendas of key leadership meetings)• Sponsored key initiatives as Oncology R&D representative on Gaithersburg (Maryland) Site Leadership Team, overseeing 5000+ local employees

• Directly supported SVP, Head of Early Oncology R&D (Dr. Jean-Charles Soria) as Chief of Staff• Led highly strategic initiatives and efforts across Early Oncology R&D leadership team and other senior leaders; owned business process deliverables and supported short, mid and long-term planning (MTP, LTP)• Ensured strong collaboration and interaction among Early Oncology R&D leadership team functions including Clinical, Translational, Discovery, Strategy, External Alliances/Partnerships, Project Leadership and Business Operations• Collaborated closely across all enabling functions (Finance, HR, Comms, etc) to deliver our scorecard and strategic goals, budget setting and tracking process, recruitment/HR activities, organizational design, internal and external communications and other key operational activities• Managed 15-person Early Oncology R&D leadership team

Promoted from Senior Manager to Associate Director in 2018.• Alliance Leadership: Managed cross-functional internal and external global teams consisting of R&D representatives from BD, Legal, IP, Contracts, Finance, PM, Research, Translational, Tox, CMC, Clinical Dev/Ops, Regulatory and Commercial; Experience managing alliances with emerging Biotech and global Biopharma in US, Europe and Asia / China; Led Joint Steering Committee meetings with Senior Leadership at MedImmune and partner companies (C-suite level); Led management of Board of Directors meeting for Joint Venture with key strategic partner in China; Led efforts to optimize MedImmune alliance capabilities in-house via reporting, sharing lessons learned, document mgmt, training• Oncology External Development Leadership: Led and managed Oncology (focusing on phase 1 and 2 IO clinical programs) activities with key institutions, PIs and government agencies; managed strategic approach to partnering and outreach, as well as ensuring protocols are reviewed and approved efficiently via collaboration with internal stakeholders (Clinical Ops, Clinical Dev, TS, Research, BD, others); Managed study progress, finances and communication to senior leaders• R&D Project Management: Managed projects across various TAs in varying stages of R&D (preclinical, IND submission, and clinical phase 1 and 2) via in-house development and external alliances; Focus on project timelines, deliverables, milestones, quality, resource management, budgets and risk mitigation• Founding Member of R&D Biologics Alliance Management leadership team; received first-ever Alliance Mgmt Excellence Award for MedImmune (from external global organization ASAP, 2018)

• Optimizing existing molecules ideation workshop design / facilitation: prepared for, designed, and facilitated 4 workshops with 20+ global stakeholders across various functions (R&D, Manufacturing, Marketing, Regulatory, IP, Market Access, and Medical/Clinical) to develop and vet ideas to maximize value of existing generic assets/products• Co-development collaboration termination: led alliance and project management activities across 10+ workstreams including Clinical Science, Database Science, CMC, CTM, Safety/PV, Regulatory, Legal/Contracts, Publications, and Commercialization; led vendor/site contract assignment documentation; major contributor to transition agreement development• Product launch preparation for a new indication: supported project management coordination activities across Medical Affairs, Marketing, Market Access, PR/Communications and Sales teams• Commercial organizational structure design optimization: clarified activities and RACIs across Market Access, Communications, Sales, Brand, Business Analytics, Emerging Products, Program Management, and HR/Administrative support teams• New product planning team design: developed and formalized future state recommendations through internal/external KOL interviews, case studies, and a current state analysis• Internal HR recruitment strategy and toolkit development: co-led team that created candidate sourcing, screening, job requirement, key messaging, and internal/external communication guide deliverables• Led internal consulting team of 5 staff consultants; managed life science specific recruitment and on-boarding/training for new hires, among other internal initiatives• TA experience in Oncology, Parkinson’s, Huntington’s, Schizophrenia, Sleep Disorders, Pain, Infectious Diseases (HIV), Diabetes, Gastrointestinal, Obesity, and HAE

Global Bioassays and Technology (GB&T)Promoted to Research Associate III (from Research Associate II) in February, 2012• Researched, developed, qualified, validated, and ran samples in potency, pharmacokinetic (PK), and immunogenicity assays in non-clinical and human clinical studies involving biologics (innovative and biosimilar/biobetter) and generic small molecule drugs• Lead analyst during non-clinical and clinical validation and sample analysis PK studies – managed secondary analyst(s)• Laboratory Information Management System (LIMS) sample manager – received shipments, organized samples, and conducted data analysis• Leveraged RHT Consulting experience to propose and develop a portfolio management plan at Teva Biopharmaceuticals USA; developed high-level NPV and IRR analysis of biologics portfolio

• Developed 3-year strategic plan for local, clinical-stage pharmaceutical company focusing on novel treatments for infectious diseases• Scheduled and conducted 20 interviews with company personnel and external subject matter experts to gain insight into core competency areas including disease, technical, and drug process timeline expertise• Researched private/public industry, university, and government institutions for potential business development activities (licensing, M&A)• Major contributor to market analysis of 50 disease areas by examining 40 dimensions including incidence rate, unmet need, geographical prevalence, development complexity, ability to execute, market size, scientific assessment, and competitive intensity• Participated daily in virtual and in-person team meetings with over 20 verbal and written deliverables

• First author on PNAS paper, June 2012 (Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor) - see link to paper below• Conducted basic biomedical research involving HIV-1 related cytokines and cytokine receptors in the Laboratory of Immunoregulation in the National Institute of Allergy and Infectious Diseases under Dr. Paolo Lusso (within Dr. Anthony Fauci’s team)• Utilized nearly 20 immunological techniques to study HIV-1 related cytokines; summarized experiments and compiled reports weekly